SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease-Reference-Cited by-同舟云学术

SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease

Published:2023-06 Issue:18 Volume:30 Page:2039-2060
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

Sarafidis Pantelis¹^ORCID,Pella Eva¹^ORCID,Kanbay Mehmet²^ORCID,Papagianni Aikaterini¹^ORCID

Affiliation:

1. Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

2. Department of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey

Abstract

Abstract: For several years, blood pressure control and blocking of the renin-angiotensin system (RAS) represented the cornerstones of chronic kidney disease (CKD) treatment. Cardiovascular outcome trials with sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus (DM) suggested that these agents can effectively delay the progression of CKD in these individuals. A major nephroprotective effect of canagliflozin was also shown in a renal outcome trial in patients with proteinuric diabetic CKD. The Study-to- Evaluate-the-Effect- of-Dapagliflozin-on-Renal-Outcomes-and-Cardiovascular- Mortality-in-Patients-With-Chronic-Kidney-Disease (DAPA-CKD) is a recent milestone in the field, as it included patients with both diabetic and non-diabetic proteinuric CKD and showed impressive reduction in the primary renal outcome of CKD progression, as well as the risk of hospitalization for heart failure and all-cause mortality on top of standard- of-care treatment. These benefits were consistent for patients with diabetic and non-diabetic CKD, including patients with ischemic or hypertensive nephropathy and glomerulonephritides (IgA nephropathy, focal segmental glomerulosclerosis and membranous nephropathy). Based on the above, relevant guidelines should accommodate their recommendations to implement treatment with SGLT-2 inhibitors for CKD patients.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry

Reference100 articles.

1. Jager K.J.; Kovesdy C.; Langham R.; Rosenberg M.; Jha V.; Zoccali C.; A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019,96(5),1048-1050

2. Bikbov B.; Purcell C.A.; Levey A.S.; Smith M.; Abdoli A.; Abebe M.; Adebayo O.M.; Afarideh M.; Agarwal S.K.; Agudelo B.M.; Ahmadian E.; Al-Aly Z.; Alipour V.; Almasi-Hashiani A.; Al-Raddadi R.M.; Alvis G.N.; Amini S.; Andrei T.; Andrei C.L.; Andualem Z.; Anjomshoa M.; Arabloo J.; Ashagre A.F.; Asmelash D.; Ataro Z.; Atout M.M.W.; Ayanore M.A.; Badawi A.; Bakhtiari A.; Ballew S.H.; Balouchi A.; Banach M.; Barquera S.; Basu S.; Bayih M.T.; Bedi N.; Bello A.K.; Bensenor I.M.; Bijani A.; Boloor A.; Borzì A.M.; Cámera L.A.; Carrero J.J.; Carvalho F.; Castro F.; Catalá-López F.; Chang A.R.; Chin K.L.; Chung S.C.; Cirillo M.; Cousin E.; Dandona L.; Dandona R.; Daryani A.; Das Gupta R.; Demeke F.M.; Demoz G.T.; Desta D.M.; Do H.P.; Duncan B.B.; Eftekhari A.; Esteghamati A.; Fatima S.S.; Fernandes J.C.; Fernandes E.; Fischer F.; Freitas M.; Gad M.M.; Gebremeskel G.G.; Gebresillassie B.M.; Geta B.; Ghafourifard M.; Ghajar A.; Ghith N.; Gill P.S.; Ginawi I.A.; Gupta R.; Hafezi N.N.; Haj M.A.; Haj M.A.; Hariyani N.; Hasan M.; Hasankhani M.; Hasanzadeh A.; Hassen H.Y.; Hay S.I.; Heidari B.; Herteliu C.; Hoang C.L.; Hosseini M.; Hostiuc M.; Irvani S.S.N.; Islam S.M.S.; Jafari Balalami N.; James S.L.; Jassal S.K.; Jha V.; Jonas J.B.; Joukar F.; Jozwiak J.J.; Kabir A.; Kahsay A.; Kasaeian A.; Kassa T.D.; Kassaye H.G.; Khader Y.S.; Khalilov R.; Khan E.A.; Khan M.S.; Khang Y.H.; Kisa A.; Kovesdy C.P.; Kuate Defo B.; Kumar G.A.; Larsson A.O.; Lim L.L.; Lopez A.D.; Lotufo P.A.; Majeed A.; Malekzadeh R.; März W.; Masaka A.; Meheretu H.A.A.; Miazgowski T.; Mirica A.; Mirrakhimov E.M.; Mithra P.; Moazen B.; Mohammad D.K.; Mohammadpourhodki R.; Mohammed S.; Mokdad A.H.; Morales L.; Moreno Velasquez I.; Mousavi S.M.; Mukhopadhyay S.; Nachega J.B.; Nadkarni G.N.; Nansseu J.R.; Natarajan G.; Nazari J.; Neal B.; Negoi R.I.; Nguyen C.T.; Nikbakhsh R.; Noubiap J.J.; Nowak C.; Olagunju A.T.; Ortiz A.; Owolabi M.O.; Palladino R.; Pathak M.; Poustchi H.; Prakash S.; Prasad N.; Rafiei A.; Raju S.B.; Ramezanzadeh K.; Rawaf S.; Rawaf D.L.; Rawal L.; Reiner R.C.; Rezapour A.; Ribeiro D.C.; Roever L.; Rothenbacher D.; Rwegerera G.M.; Saadatagah S.; Safari S.; Sahle B.W.; Salem H.; Sanabria J.; Santos I.S.; Sarveazad A.; Sawhney M.; Schaeffner E.; Schmidt M.I.; Schutte A.E.; Sepanlou S.G.; Shaikh M.A.; Sharafi Z.; Sharif M.; Sharifi A.; Silva D.A.S.; Singh J.A.; Singh N.P.; Sisay M.M.M.; Soheili A.; Sutradhar I.; Teklehaimanot B.F.; Tesfay B.; Teshome G.F.; Thakur J.S.; Tonelli M.; Tran K.B.; Tran B.X.; Tran Ngoc C.; Ullah I.; Valdez P.R.; Varughese S.; Vos T.; Vu L.G.; Waheed Y.; Werdecker A.; Wolde H.F.; Wondmieneh A.B.; Wulf Hanson S.; Yamada T.; Yeshaw Y.; Yonemoto N.; Yusefzadeh H.; Zaidi Z.; Zaki L.; Zaman S.B.; Zamora N.; Zarghi A.; Zewdie K.A.; Ärnlöv J.; Coresh J.; Perico N.; Remuzzi G.; Murray C.J.L.; Vos T.; Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020,395(10225),709-733

3. Go A.S.; Chertow G.M.; Fan D.; McCulloch C.E.; Hsu C.; Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004,351(13),1296-1305

4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013,3(1),1-150

5. Foreman K.J.; Marquez N.; Dolgert A.; Fukutaki K.; Fullman N.; McGaughey M.; Pletcher M.A.; Smith A.E.; Tang K.; Yuan C.W.; Brown J.C.; Friedman J.; He J.; Heuton K.R.; Holmberg M.; Patel D.J.; Reidy P.; Carter A.; Cercy K.; Chapin A.; Douwes S.D.; Frank T.; Goettsch F.; Liu P.Y.; Nandakumar V.; Reitsma M.B.; Reuter V.; Sadat N.; Sorensen R.J.D.; Srinivasan V.; Updike R.L.; York H.; Lopez A.D.; Lozano R.; Lim S.S.; Mokdad A.H.; Vollset S.E.; Murray C.J.L.; Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018,392(10159),2052-2090

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin restores autophagy and attenuates apoptosis via the AMPK/mTOR pathway in diabetic nephropathy rats and high glucose-induced HK-2 cells;International Urology and Nephrology;2024-07-29

2. Progress of SGLT2 inhibitors in the treatment of common immune-related nephropathies;International Urology and Nephrology;2024-07-04

3. Proximal tubule hypertrophy and hyperfunction: a novel pathophysiological feature in disease states;Clinical Kidney Journal;2024-06-25

4. Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks;Archives of Pharmacy and Pharmaceutical Sciences;2024-05-02

5. Eucommia lignans alleviate the progression of diabetic nephropathy through mediating the AR/Nrf2/HO-1/AMPK axis in vivo and in vitro;Chinese Journal of Natural Medicines;2023-07